MedMira is a Canadian biotechnology company dedicated to provide high-quality rapid testing solutions using our patented Rapid Vertical Flow® (RVF) Technology platform in efforts to improve the quality of disease diagnosis and management. RVF® Technology enables best-in-class speed, multiplex results, and versatility in any setting.

RVF® Technology is the basis for MedMira’s commercialized product range that helps healthcare providers and agencies combat HIV, hepatitis, syphilis, and other infectious and sexually transmitted diseases. We have also established a research product line that facilitates technology licensing, contract manufacturing, and regulatory consulting revenue streams by making MedMira RVF® Technology available to other researchers and collaborators for the development and commercialization of new rapid tests.

Faced with decreasing budgets and resources, healthcare providers require high-quality rapid tests that are reliable in every way, from performance to results. With the unique capability of a single device to enable multiplex screening using just a single drop of specimen, we are delivering a new class of rapid testing solutions to our customers.

Our technology platform is a practical and scalable innovation that has the potential to improve the well-being of people around the world. RVF® Technology is the core engine behind our world-class rapid testing solutions for infectious, sexually transmitted diseases and other chronic healthcare conditions.

Speed and multiplexing are the hallmarks of our technology, which has endured the most rigorous medical device approval processes in the world and has been validated by healthcare providers, governments, and aid organizations. Our technology has been proven in highly complex regulatory markets around the world including the United States (FDA), Canada (Health Canada), Europe (CE) and China (CFDA).

Awards: 2008 Tech Awards Laureate of the Tech Museum of Innovation

The Economist 2007 Innovation Award: Bioscience
OUR DISTINCT TECHNOLOGY

Our RVF® platform is unique in its ability to detect multiple biomarkers, specific to different diseases, using a single cartridge. Our Multiplo line of rapid tests for HIV, Hepatitis B and C, and syphilis uses the platform’s advanced capabilities to deliver up to four test results using just a single drop of specimen.

Features:

- A 3-step test procedure
- Instant results
- Whole blood, serum or plasma matrices
- Up to 24-month shelf-life at 2 – 30° C
- Compact, single-use package, no refrigeration required
- Built-in procedural and reagent control line

MedMira’s RVF® Technology is at the center of our current and future success. There are four rapid testing technologies currently used in building rapid tests and only two are patented. In addition to being the fastest of these technologies, MedMira’s RVF® platform has a distinct competitive advantage of multiplexing, which increases efficiency and decreases the overall cost for customers. Based on these unique capabilities, we have secured a number of high value contracts and regularly attract world-class collaborators.

Testing applications for our products include public health programs, Voluntary Testing & Counselling Centers (VCTs), pharmacies, physician offices, immigration screening, occupational exposures, convenience care clinics, correctional facilities, and more.

Helping people know…

Awards

2007 The Economist Innovation Award: Bioscience

2008 Tech Awards Laureate of the Tech Museum of Innovation

2012 Canadian Manufacturer’s & Export New Technology Award

2014 Outstanding Business Innovation Award Canada – Hong Kong Canada Business Achievement Award

OUR TARGET MARKETS AND CUSTOMERS

We sell our products through a network of medical distributors and strategic business development partners with customers in various sectors of the healthcare industry, including laboratories, hospitals, point-of-care clinics, governments, and public health agencies. MedMira works with well-established local partners who possess regional market expertise and relationships, in-depth knowledge of diagnostics, and best-of-breed business practices.

Our main focus market is the United States which has the highest entry barrier due to its stringent FDA approval process, but also elicits the best opportunities and is well suited to MedMira’s high-quality products. In addition, through a solid distribution network, MedMira is selling its products in Europe and other markets, which require the highest quality and speed.
Contact Information

MedMira Inc.
155 Chain Lake Drive
Halifax, N.S. Canada
B3S 1B3
Canada

P: +1 902 450 1580

Disclaimer

The material in this presentation has been prepared by MedMira Inc. (MedMira) and is general, up-to-date background information about MedMira’s activities. This information is given as a summary and does not purport to be complete. Information in this presentation, including forecast financial information, should not be considered as advice or a recommendation to investors or potential investors in relation to holding, purchasing or selling securities or other financial products or instruments, and does not take into account your particular investment objectives, financial situation or needs. Before acting on any information you should consider the appropriateness of the information having regard to these matters, any relevant offer document, and, in particular, you should seek independent financial advice. All securities and financial product or instrument transactions involve risks, which include (among others) the risk of adverse or unanticipated market, financial or political developments, and, in international transactions, currency risk.

This presentation may contain forward-looking statements, including statements regarding our intent, belief or current expectations with respect to MedMira’s businesses and operations, market conditions, results of operation and financial condition, capital adequacy, specific provisions and risk management practices. Readers are cautioned not to place undue reliance on these forward-looking statements. MedMira does not undertake any obligation to publicly release the result of any revisions to these statements to reflect events or circumstances after the date hereof to reflect the occurrence of unanticipated events. While due care has been taken in the preparation of forecast information, actual results may vary in a materially positive or negative manner. Forecasts and hypothetical examples are subject to uncertainty and contingencies outside MedMira’s control. Past performance is not a reliable indication of future performance.